Why the study?
Does pharmacologic reduction of Lp(a) concentration decrease CAD risk without increasing T2D risk?
Does pharmacologic reduction of Lp(a) concentration decrease CAD risk without increasing T2D risk?
Pharmacologic reduction of high Lp(a) to median levels is predicted to lower CAD risk without the adverse effect of increasing T2D risk seen at very low Lp(a) levels.
No takes yet. Share an insight, caveat, or question.
May support targeted Lp(a) lowering to median for CAD benefit without T2D risk; hypothesis-generating and requires RCT confirmation.
Guðbjartsson et al. (2019) studied this question.